JAZZ
Jazz Pharmaceuticals plc
NASDAQ · Healthcare · Biotechnology · IE
$246.81
−0.30%Aug 31, 2026, 10:00 UTC
Jazz Pharmaceuticals announced second interim overall survival results from the Phase 3 HERIZON-GEA-01 trial showing Ziihera plus chemotherapy significantly improved overall survival versus trastuzumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma.
Aug 27, 2026, 04:30 UTC
Jazz Pharmaceuticals announced concurrent ordinary share repurchases in connection with the pricing of its exchangeable senior notes offering.
Source:Aug 26, 2026, 11:00 UTC
Jazz Pharmaceuticals announced a private offering of $1.0 billion aggregate principal amount of exchangeable senior notes due 2032, with an option for initial purchasers to buy up to an additional $150 million.
Source:Aug 26, 2026, 00:02 UTC
Jazz Pharmaceuticals announced plans for the U.S. launch of Ziihera, a therapy approved by the FDA for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
Aug 25, 2026, 14:00 UTC
The U.S. FDA approved Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) with and without tislelizumab plus chemotherapy for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma.
Aug 10, 2026, 11:30 UTC
Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent consideration, adding the clinical-stage precision therapy ABS-1230 for KCNT1+ epilepsy.
Aug 3, 2026, 20:05 UTC
Jazz Pharmaceuticals announced its second quarter 2026 financial results, reporting record total revenues of $1.2 billion, a 16% increase year-over-year.
Jun 17, 2026, 11:43 UTC
Jazz Pharmaceuticals and AbCellera entered into a research collaboration and licensing agreement to develop T-cell engaging multispecific antibodies for cancer.
Jun 12, 2026, 12:53 UTC
Jazz Pharmaceuticals' lung cancer drug Zepzelca failed to meet the main goal of improving overall survival in a late-stage study.
Source: